Prevention and treatment of the consequences of head and neck radiotherapy

Critical Reviews in Oral Biology and Medicine

Volumn 14, Issue 3, 2003, Pages 213-225

  Vissink, A ^a   Burlage, F R ^a   Spijkervet, F K L ^a   Jansma, J ^a   Coppes, R P ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Caries; Mucositis; Osteoradionecrosis; Prevention; Radiotherapy; Treatment; Xerostomia

Indexed keywords

ACID; AMIFOSTINE; AMPHOTERICIN B; ANALGESIC AGENT; ANESTHETIC AGENT; ANETHOLE TRITHIONE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASCORBIC ACID; BENZYDAMINE; CARBACHOL; CEVIMELINE; CHLORHEXIDINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITRIC ACID; COLISTIN; GLYCEROL; LIDOCAINE; NEOSTIGMINE; NICOTINAMIDE; NICOTINIC ACID; PILOCARPINE; POTASSIUM IODIDE; PYRIDOSTIGMINE; SALIVA SUBSTITUTE; SIALOGOGUE DERIVATIVE; SUCRALFATE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC; MUSCARINIC AGENT;

AGEUSIA; BONE NECROSIS; CANCER RADIOTHERAPY; CELL PROTECTION; CHEWING GUM; CLINICAL TRIAL; DEBRIDEMENT; DENTAL CARIES; FOOD INTAKE; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; HYPERBARIC OXYGEN; HYPOSALIVATION; JAW; LYMPH NODE METASTASIS; META ANALYSIS; MOUTH CAVITY; MOUTH HYGIENE; MUCOSA INFLAMMATION; NONHUMAN; PAIN; PERIODONTAL DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; SALIVARY GLAND; SYSTEMATIC REVIEW; TREATMENT PLANNING; TRISMUS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; DYSGEUSIA; HEAD AND NECK TUMOR; JAW DISEASE; MOUTH DISEASE; MOUTH MUCOSA; RADIATION EXPOSURE; SKULL IRRADIATION; STOMATITIS;

ANTI-BACTERIAL AGENTS; CRANIAL IRRADIATION; DENTAL CARIES; DYSGEUSIA; HEAD AND NECK NEOPLASMS; HUMANS; JAW DISEASES; MOUTH DISEASES; MOUTH MUCOSA; MUSCARINIC AGONISTS; OSTEORADIONECROSIS; PILOCARPINE; STOMATITIS; TRISMUS; XEROSTOMIA;

EID: 0037867774     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130301400306     Document Type: Review

References (188)

1. Adamietz IA, Rahn R, Böttcher HD, Schäfer V, Reimer K, Fleischer W (1998). Prophylaxe der radiochemotherapeutisch bedingten Mukositis. Strahlenther Onkol 174:149-155.
2. Anderson G, Johansson G, Attström R, Edwardsson S, Glantz PO, Larsson K (1995). Comparison of the effect of linseed extract Salinum and a methyl cellulose preparation on the symptoms of dry mouth. Gerodontology 12:12-17.
3. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N (2002). Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 52:739-747.
4. Atkinson JC, Baum BJ (2001). Salivary enhancement: current status and future therapies. J Dent Educ 65:1096-1101.
5. Baum BJ, O'Connell BC (1999). In vivo gene transfer to salivary glands. Crit Rev Oral Biol Med 10:276-283.
6. Bensadoun RJ, Magne N, Marcy PY, Demard F (2001). Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology. Prevention and treatment. Eur Arch Otorhinolaryngol 258:481-487.
7. Beumer J, Brady FA (1978). Dental management of the irradiated patient. Int J Oral Surg 7:208-220.
8. Beumer J, Curtis T, Harrison R (1979a). Radiation therapy of the oral cavity: sequelae and management, Part 1. Head Neck Surg 1:301-312.
9. Beumer J, Curtis T, Harrison R (1979b). Radiation therapy of the oral cavity: sequelae and management, Part 2. Head Neck Surg 1:392-408.
10. Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Månsson B (1996). Acupuncture treatment of patients with radiationinduced xerostomia. Oral Oncol Eur J Cancer 32(B):182-190.
11. Borowski E, Benhamon E, Pico JL, Laplance A, Margainaud JP, Hayat M (1994). Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation. A randomised controlled trial comparing two protocols of dental care. Oral Oncol Eur J Cancer 30(B):93-97.
12. Buntzel J, Glazel M, Kuttner K, Weinaug R, Frohlich D (2002). Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Sem Radiat Oncol 12(Suppl 1):4-13.
13. Carl W, Schaaf NG (1974). Dental care for the cancer patient. J Surg Oncol 6:293-310.
14. Consensus statement (1990). Oral complications of cancer therapies. NCI Monogr 9:3-8.
15. Constantino PD, Friedman CD, Steinberg MJ (1995). Irradiated bone and its management. Otolaryngol Clin North Am 28:1021-1038.
16. Cooper JS, Fu K, Marks J, Silverman S (1995). Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 31:1141-1164.
17. Coppes RP, Zeilstra LJW, Vissink A, Konings AWT (1997a). Sialogogue-related radioprotection of salivary gland function: the degranulation concept revisited. Radiat Res 148:240-247.
18. Coppes RP, Vissink A, Zeilstra LJW, Konings AWT (1997b). Muscarinic receptor stimulation increases tolerance of rat salivary gland function to radiation damage. Int J Radiat Biol 72:615-625.
19. Coppes RP, Zeilstra LJW, Kampinga HH, Konings AWT (2001). Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists. Br J Cancer 85:1055-1063.
20. Curi MM, Dib LL (1997). Osteoradionecrosis of the jaws: a retrospective study on the background factors and treatment in 104 cases. J Oral Maxillofac Surg 55:540-544.
21. Curtis TA, Griffith M, Firtell DN (1976). Complete denture prosthodontics for the radiation patient. J Prosthet Dent 36:66-76.
22. Daly TE, Drane JB (1976). Prevention and management of dental problems in irradiated patients. J Am Soc Prev Dent 6:21-25.
23. Daly TE, Drane JB, MacComb WS (1972). Management of problems of the teeth and jaws in patients undergoing irradiation. Am J Surg 124:539-542.
24. Del Regato JA (1939). Dental lesions observed after Roentgen therapy in cancer of the buccal cavity, pharynx and larynx. Am J Roentgenol 42:404-410.
25. Delporte C, O'Connell BC, He X, Lancaster HE, O'Connell AC, Agre P, et al. (1997). Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA 94:3268-3273.
26. Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, et al. (1999). Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol 52:157-164.
27. Dörr W, Noack R, Spekl K, Farrell CL (2001). Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 77:341-347.
28. Dreizen SA, Brown LR, Daly TE, Drane JB (1977a). Prevention of xerostomia-related dental caries in irradiated cancer patient. J Dent Res 56:99-104.
29. Dreizen SA, Daly TE, Drane JB, Brown LR (1977b). Oral complications of cancer radiotherapy. Postgrad Med 61:85-92.
30. Eisbruch A, Ten Haken RK, Hyungjin MK, Marsh LH, Ship JA (1999). Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577-587.
31. Eisbruch A, Ship JA, Kim HM, Ten Haken RK (2001). Partial radiation of the parotid gland. Sem Radiat Oncol 11:234-239.
32. El-Sayed S, Epstein JB, Minish E, Burns P, Hay J, Laukkanen E (2002). A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck 24:6-15.
33. Engelmeier RL, King GE (1983). Complications of head and neck radiation therapy and their management. J Prosthet Dent 49:514-522.
34. Epstein JB (1990). Infection prevention in bone marrow transplantation and radiation patients. NCI Monogr 9:73-85.
35. Epstein JB, Schubert MM (1987). Synergistic effect of sialogogues in management of xerostomia after radiation therapy. Oral Surg Oral Med Oral Pathol 64:179-182.
36. Epstein JB, Stevenson-Moore P (2001). Periodontal disease and periodontal management in patients with cancer. Oral Oncol 37:613-619.
37. Epstein JB, Wong FLW, Stevenson-Moore P (1987a). Osteoradionecrosis: clinical experience and a proposal for classification. J Oral Maxillofac Surg 45:104-110.
38. Epstein JB, Rea G, Wong FLW (1987b). Osteonecrosis: study of the relationship of dental extractions in patients receiving radiotherapy. Head Neck Surg 10:48-54.
39. Epstein JB, Vickars L, Spinelli J, Reece D (1992). Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73:682-689.
40. Epstein JB, Burchell JL, Emerton S, Le ND, Silverman S (1994). A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surg Oral Med Oral Pathol 77:610-614.
41. Epstein JB, van der Meij EH, Emerton SM, Le ND, Stevenson-Moore P (1995). Compliance with fluoride gel use in irradiated patients. Spec Care Dentist 15:218-222.
42. Epstein JB, van der Meij EH, Lunn R, Stevenson-Moore P (1996). Effects of compliance with fluoride gel application on caries and caries risk inpatients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Radiol Endod 82:268-2757.
43. Epstein JB, van der Meij EH, McKenzie M, Wong F, Lepawsky M, Stevenson-Moore P (1997). Postradiation osteonecrosis of the mandible. A long-term follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83:657-662.
44. Epstein JB, Lunn R, Le ND, Stevenson-Moore P (1998). Periodontal attachment loss in patients after head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86:673-677.
45. Epstein JB, Emerton S, Kolbinson DA, Le ND, Philips N, Stevenson-Moore P, et al. (1999a). Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 21:1-11.
46. Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999b). A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35:132-137.
47. Erkurt E, Erkisi M, Tunali C (2000). Supportive treatment in weight losing cancer patients due to the additive adverse effects of radiation treatment. J Exp Clin Cancer Res 19:431-439.
48. Farrell CL, Rex KL, Kaufman SA, Dipalma CR, Chen JN, Scully S, et al. (1999). Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 75:606-620.
49. Fleming TJ (1983). The use of topical fluoride by patients receiving cancer therapy. Curr Probl Cancer 7:37-41.
50. Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH, et al. (1994). Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 12:2630-2633.
51. Franzén L, Henriksson R, Littbrand B, Zackrisson B (1995). Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. Acta Oncologica 34:219-223.
52. Friedman RB (1990). Osteoradionecrosis: causes and prevention. NCI Monogr 9:145-149.
53. Frisch J, Sproull R (1962). Dental treatment after irradiation. J Prosthet Dent 12:182-189.
54. Gelhard TBFM, Fidler V, 's-Gravenmade EJ, Vissink A (1983). Remineralization of softened human enamel in mucin- or CMC-containing artificial salivas. J Oral Pathol 12:336-341.
55. Goldstein M, Maxymiw WG, Cummings BJ, Wood RE (1999). The effects of antitumour irradiation on mandibular opening and mobility. A prospective study of 58 patients. Oral Surg Oral Med Oral Pathol Endod 88:365-373.
56. Greenspan D (1990). Management of salivary dysfunction. NCI Monogr 9:159-161.
57. Greenspan D, Daniels TE (1987). Effectiveness of pilocarpine in postradiation xerostomia. Cancer 59:1123-1125.
58. Hao SP, Chen HC, Wei FC, Chen CY, Yeh ARM, Su JL (1999). Systematic management of osteoradionecrosis in the head and neck. Laryngoscope 109:1324-1328.
59. Hassenstein E, Muller R, Reinhard HJ (1978). Die Wirkung von SL 25 auf die radiogene Xerostomie bei der Strahlentherapie von Tumoren im Hals- und Gesichtsbereich. Strahlentherapie 154:554-558.
60. Hazuka MB, Martel MK, Marsh L, Lichter AS, Wolf GT (1993). Preservation of parotid function after external beam irradiation in head and neck cancer patients: a feasibility study using 3-dimensional treatment planning. Int J Radiat Oncol Biol Phys 27:731-737.
61. Henson BS, Inglehart MR, Eisbruch A, Ship JA (2001). Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 37:84-93.
62. Horiot JC, Bone MC, Ibrahim E, Castro JR (1981). Systematic dental management in head and neck irradiation. Int J Radiat Oncol Biol Phys 7:1025-1029.
63. Horiot JC, Schraub S, Bone MC, Bain Y, Ramadier J, Chaplain G, et al. (1983). Dental preservation in patients irradiated for head and neck tumours: a 10-year experience with topical fluoride and a randomized trial between two fluoridation methods. Radiother Oncol 1:77-82.
64. Horiot JC, Maingon P, Barillot I (1994). Radiotherapy for head and neck cancers including chemoradiotherapy. Curr Opin Oncol 6:274-276.
65. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, et al. (2000). Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiat Oncol 55:233-239.
66. Jansma J, Vissink A, 's-Gravenmade EJ, Visch LL, Fidler V, Retief DH (1989). In vivo study on the prevention of post-radiation caries. Caries Res 23:172-178.
67. Jansma J, Vissink A, Spijkervet FKL, Panders AK, Vermey A, Roodenburg JLN, et al. (1992). Protocol for the prevention and treatment of oral complications of head and neck radiotherapy. Cancer 70:2171-2180.
68. Jellema AP, Langendijk H, Bergenhenegouwen L, van der Reijden WA, Leemans R, Smeele L, et al. (2001). The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 59:157-160.
69. Jha N, Seikaly H, McGaw T, Coulter L (2000). Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 46:7-11.
70. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49.
71. Joensuu H, Bostrom P, Makkonen T (1993). Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. Radiother Oncol 26:33-37.
72. Johansson G, Andersson G, Attström R, Edwardsson S (2000). Oral mucous membrane flora in patients using saliva substitutes. Gerodontology 17:87-90.
73. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. (1993). Oral pilocarpine for postirradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390-395.
74. Johnstone PA, Peng YP, May BC, Inouye WS, Neimtzow RC (2001). Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 50:353-357.
75. Jones RE, Takeuchi T, Eisbruch A, D'Hondt E, Hazuka M, Ship JA (1996). Ipsilateral parotid sparing study in head and neck cancer patients who receive radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:642-648.
76. Joyston-Bechal S, Hayes K, Davenport ES, Hardie JM (1992). Caries incidence, mutans streptococci and lactobacilli in irradiated patients during a 12-month preventive programme using chlorhexidine and fluoride. Caries Res 26:384-390.
77. Karthaus M, Rosenthal C, Ganser A (1999). Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis. Are there new strategies? Bone Marrow Transplant 24:1095-1108.
78. Kielbassa AM, Shohadai SP, Schulte-Mönting J (2000). Effect of saliva substitutes on mineral content of demineralized and sound dental enamel. Support Care Cancer 9:40-47.
79. Klestov AC, Webb J, Latt D, Schiller G, McNamara K, Young DY, et al. (1981). Treatment of xerostomia: a double blind trial in 108 patients with Sjögren's syndrome. Oral Surg 51:594-599.
80. Lajtman Z, Krajina Z, Krpan D, Vincelj J, Borcic V, Popovic-Kovacic J (2000). Pilocarpine in the prevention of postirradiation xerostomia. Acta Med Croatica 54:65-67.
81. Lees J (1999). Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional cancer cenre. Eur J Cancer Care 8:133-136.
82. Leslie MD, Dishe S (1991). Parotid gland function following accelerated and conventionally fractionated radiotherapy. Radiother Oncol 22:133-139.
83. Leslie MD, Dishe S (1994). The early changes in salivary gland function during and after radiotherapy given for head and neck cancer. Radiother Oncol 30:26-32.
84. LeVeque FG, Montgomery F, Potter D, Zimmer M, Rieke JW, Steiger BW, et al. (1993). A multi-centre randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11:1124-1131.
85. Levine MJ (1993). Development of artificial salivas. Crit Rev Oral Biol Med 4:279-286.
86. Licht R, Kampinga HH, Coppes RP (2002). Salivary gland sparing prophylactic pilocarpine treatment has no effect on tumor regrowth after irradiation. Radiat Res 157:596-598.
87. Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L, et al. (1998). Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 47:149-153.
88. Lockhart PB (1986). Oral complications of radiation therapy. In: Head and neck management of the cancer patient. Peterson DE, Elias EG, Sonis ST, editors. Boston: Martinus Nijhoff, pp. 275-297.
89. Maciejewski B, Zajusz A, Pilecki B, Swiatnicka J, Skaldowski K, Dörr W, et al. (1991). Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer. Radiother Oncol 22:7-11.
90. Makkonen TA, Kiminki A, Makkonen TK, Nordman E (1987). Dental extractions in relation to radiation therapy of 224 patients. Int J Oral Maxillofac Surg 16:56-64.
91. Makkonen TA, Boström P, Vilja P, Joensuu H (1994). Sucralfate mouth washing in the prevention of radiation-induced mucositis. A placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 30:177-182.
92. Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joensuu H (2000). Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in preventin of radiation-induced mucositis. A prospective randomized study. Int J Radiat Oncol Biol Phys 46:525-534.
93. Martin HE, Sugarbaker EL (1940). Cancer of the floor of the mouth. Surgery Gynec Obstet 71:347-359.
94. Martin MV (1993). Irradiation mucositis: a reappraisal. Oral Oncol Eur J Cancer 29B:1-2.
95. Martin MV, van Saene HKF (1992). The role of microorganisms in cancer therapy. Oral Maxillofac Surg Infect 2:81-84.
96. Marx RE (1983). A new concept in the treatment of osteoradionecrosis. J Oral Maxillofac Surg 41:351-357.
97. Marx RE (1984). Osteonecrosis of the jaws: a review and update. Hyperbaric Oxygen Rev 5:78-127.
98. Marx RE, Johnson RP (1987). Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 64:379-390.
99. Marx RE, Johnson RP, Kline SN (1985). Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc 111:49-54.
100. Mascarin M, Franchin G, Minatel E, Gobitti C, Talamini R, de Maria D, et al. (1999). The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol 35:203-208.
101. Mateos JJ, Setoain X, Ferre J, Rovisora A, Navalpotro B, Martin F, et al. (2001). Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours. Nucl Med Commun 22:651-656.
102. Matsuo R (2000). Role of saliva in the maintenance of taste sensitivity. Crit Rev Oral Biol Med 11:216-229.
103. Matzker J, Schreiber J (1972). Synthetischer Speichel zur Therapie der Hyposalien insbesondere bei der radiogenen Sialadenitis. Z Laryngol Rinol Otol 51:422-428.
104. Maxymiw WG, Wood RE, Liu FF (1991). Postradiation dental extractions without hyperbaric oxygen. Oral Surg Oral Med Oral Pathol 72:270-274.
105. McChesney SL, Gillette EL, Dewhirst MW, Withrow SJ (1986). Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys 12:1957-1963.
106. Meredith R, Salter M, Kim R, Spencer S, Weppelmann B, Rodu B, et al. (1997). Sucralfate for radiation mucositis. Results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 37:275-279.
107. Meyer-Lueckel H, Schulte-Mönting J, Kielbassa AM (2002). The effect of commercially available saliva substitutes on pre-demineralized bovine dentin in vitro. Oral Diseases 8:192-198.
108. Meyerowitz C, Featherstone JD, Billings RJ, Eisenberg AD, Fu J, Shariati M, et al. (1991). Use of an intra-oral model to evaluate 0.05% sodium fluoride mouthrinse in radiation-induced hyposalivation. J Dent Res 70:894-898.
109. Miaskowski C (1990). Management of mucositis during therapy. NCI Monogr 9:95-98.
110. Momm F, Muller M, Tsekos A, Guttenberger R (2001). Xerostomie nach Strahlentherapie. Effektivere Behandlung durch ein mucinhaltiges Spray? HNO 49:831-836.
111. Mossman KL (1986). Gustatory tissue injury in man: radiation dose response relationship and mechanism of taste loss. Br J Cancer 53:9-11.
112. Murray CG, Herson J, Daly TE, Zimmerman S (1980a). Radiation necrosis of the mandible: a 10-year study. Part I. Factors influencing the onset of necrosis. Int J Radiat Oncol Biol Phys 6:543-548.
113. Murray CG, Herson J, Daly TE, Zimmerman S (1980b). Radiation necrosis of the mandible: a 10-year study. Part II. Dental factors, onset, duration and management of necrosis. Int J Radiat Oncol Biol Phys 6:549-553.
114. Myers RAM, Marx RE (1990). Use of hyperbaric oxygen in postradiation head and neck surgery. NCI Monogr 9:151-157.
115. Newbrun E (1996). Current treatment modalities or oral problems of patients with Sjögren's syndrome. Caries prevention. Adv Dent Res 10:29-34.
116. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, Kyprianou K, Kolitsi G, Dardoufas K (1998). A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during x-irradiation therapy. A preliminary report. Int J Radiat Oncol Biol Phys 42:551-556.
117. Niedermeier W, Matthaeus C, Meyer C, Staar S, Müller RP, Schulze HJ (1998). Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86:541-549.
118. Nieuw Amerongen AV, Veerman ECI (2002). Saliva-the defender of the oral cavity. Oral Diseases 8:12-22.
119. Nishioka T, Shirato H, Arimoto T, Kaneko M, Kitahara T, Oomori K, et al. (1997). Reduction of radiation-induced xerostomia in nasopharyngeal carcinoma using CT simulation with laser patient marking and three-field irradiation technique. Int J Radiat Oncol Biol Phys 38:705-712.
120. Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J, et al. (1997). A randomized trial of a nonadsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 79:2193-2199.
121. Pankhurst CL, Smith EC, Rogers JO, Dunne SM, Jackson SH, Proctor G (1996). Diagnosis and management of the dry mouth. Part 1. Dent Update 23:56-62.
122. Papas A, Russell D, Singh M, Stack K, Kent R, Triol C, et al. (1999). Double blind clinical trial of a remineralizing dentifrice in the prevention of caries in a radiation therapy population. Gerodontology 16:2-10.
123. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P (2002). A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46:748-754.
124. Plevovà P (1999). Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis. A review. Oral Oncol 35:453-470.
125. Position Paper (1997). Periodontal considerations in the management of the cancer patient. J Periodontol 68:791-801.
126. Regelink G, Vissink A, Reintsema H, Nauta JM (1998). Efficacy of a synthetic polymer based saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int 29:383-388.
127. Regezi JA, Courtney RM, Kerr DA (1976). Dental management of patients irradiated for oral cancer. Cancer 8:994-1000.
128. Rhodus NL, Bereuter J (2000). Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. J Otolaryngol 29:28-34.
129. Rice DH, Gill G (1979). The effect of irradiation upon the bacterial flora in patients with head and neck cancer. Laryngoscope 89:1839-1841.
130. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, et al. (1995). Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 31:661-669.
131. Ripamonti C, Zecca E, Brunelli C, Fulfaro F, Villa S, Balzarini A, et al. (1998). A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 82:1938-1945.
132. Roesink JM, Konings AW, Terhaard CH, Battermann JJ, Kampinga function after radiation by prophylactic pilocarpine treatment: radiation dose dependency and compensatory mechanisms. Int J Radiat Oncol Biol Phys 45:483-489.
133. Roesink JM, Moerland MA, Battermann JJ, Hordijk GJ, Terhaard CH (2001). Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys 51:938-946.
134. Russell NS (2000). Individual variation in normal tissue reactions to radiotherapy: correlations with radiobiological parameters (thesis). Amsterdam: Free University of Amsterdam.
135. 's-Gravenmade EJ, Roukema DA, Panders AK (1974). The effects of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg 3:435-439.
136. Samarawickrama DYD (2002). Saliva substitutes: how effective and safe are they? Oral Diseases 8:177-179.
137. Sangthawan D, Watthanaarpornchai S, Phungrassami T (2001). Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. J Med Assoc Thai 84:195-203.
138. Schiødt M, Hermund NU (2002). Management of oral disease prior to radiation therapy. Support Care Cancer 10:40-43.
139. Schwartz HC, Kagan AR (2002). Osteoradionecrosis of the mandible. Scientific basis for clinical staging. Am J Clin Oncol (CCT) 25:168-171.
140. Scully C, Epstein JB (1996). Oral health care for the cancer patient. Oral Oncol Eur J Cancer 32B:281-292.
141. Senahayake F, Piggott K, Hamilton-Miller JMT (1998). A pilot study of Salix SST (saliva stimulating lozenges) in post-irradiation xerostomia. Curr Med Res Opin 14:155-159.
142. Shannon IL, McCrary BR, Starcke EN (1977). A saliva substitute for use by xerostomic patients undergoing radiotherapy to the head and neck. Oral Surg 44:656-661.
143. Shannon IL, Trodahl JN, Starcke EN (1978). Remineralization of enamel by a saliva substitute designed for use by irradiated patients. Cancer 41:1746-1750.
144. Silverman S, Chierici G (1965). Radiation therapy of oral carcinoma. I. Effects on oral tissues and management of the periodontium. J Periodontol 36:478-484.
145. Sonis ST, Woods PD, White A (1990). Pretreatment oral assessment. NCI Monogr 9:29-32.
146. Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett WH, Mulagha MT, et al. (1999). Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 85:2103-2113.
147. Spak CJ, Johnson G, Ekstrand J (1994). Caries incidence, salivary flow rate and efficacy of fluoride gel treatment in irradiated patients. Caries Res 28:388-393.
148. Spielman AI (1998). Chemosensory function and dysfunction. Crit Rev Oral Biol Med 9:267-291.
149. Spijkervet FKL, van Saene HKF, Panders AK, Vermey A, Mehta DM (1989a). Scoring irradiation mucositis in head and neck cancer patients. J Oral Pathol Med 18:167-171.
150. Spijkervet FKL, van Saene HKF, Panders AK, Vermey A, Metha DM, Fidler V (1989b). Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol 67:154-161.
151. Spijkervet FKL, van Saene HKF, van Saene JJM, Panders AK, Vermey A, Mehta DM (1990). Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med 19:486-489.
152. Spijkervet FKL, van Saene HKF, van Saene JJM, Panders AK, Vermey A, Mehta DM, et al. (1991). Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 46:167-173.
153. Sreebny LM, Zhu WX, Schwartz SS, Meek AG (1995). The preparation of an autologous saliva for use with patients undergoing therapeutic radiation for head and neck cancer. J Oral Maxillof Surg 53:131-139.
154. Starcke EN, Shannon IL (1977). How critical is the interval between extractions and irradiation in patients with head and neck malignancy. Oral Surg Oral Med Oral Pathol 43:333-337.
155. Stevenson-Moore P (1990). Essential aspects of a pretreatment oral examination. NCI Monogr 9:33-36.
156. Stewart CM, Jones AC, Bates RE, Sandow P, Pink F, Stillwell J (1998). Comparison between saliva stimulants and a saliva substitute in patients with xerostomia and hyposalivation. Spec Care Dentist 18:142-148.
157. Sutherland SE, Browman GP (2001). Prophylaxis of oral mucositis in irradiated head and neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 49:917-930.
158. Symonds RP, McIlroy P, Khorrami J, Paul J, Pyper E, Alcock SR, et al. (1996). The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 74:312-317.
159. Tenovuo J (2002). Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Diseases 8:23-29.
160. Thorn JJ, Sand Hansen H, Specht L, Bastholt L (2000). Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg 58:1088-1093.
161. Toljanic JA, Heshmati RH, Bedard JF (2002). Dental follow-up compliance in a population of irradiated head and neck cancer patients. Oral Surg Oral Med Oral Pathol Endod 93:35-38.
162. Tomita Y, Osaki T (1990). Gustatory impairment and salivary gland pathophysiology in relation to oral cancer treatment. Int J Oral Maxillofac Surg 19:299-304.
163. Tong AC, Leung AC, Cheng JC, Sham J (1999). Incidence of complicated healing and osteoradionecrosis following tooth extraction in patients receiving radiotherapy for treatment of nasopharyngeal carcinoma. Aust Dent J 44:187-194.
164. Valdez IH, Wolff A, Atkinson JC, Macynski AA, Fox PC (1993). Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 71:1848-1851.
165. Van der Reijden WA, Veerman ECI, Nieuw Amerongen AV (1994). Rheological properties of commercially available polysaccharides with potential use in saliva substitutes. Biorheology 31:631-642.
166. Van der Reijden WA, Van der Kwaak H, Vissink A, Veerman ECI, Van Nieuw Amerongen A (1996). Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthritis Rheum 39:57-69.
167. Van der Reijden WA, Buijs MJ, Damen JJ, Veerman ECI, Ten Cate JM, Nieuw Amerongen AV (1997). Influence of polymers for use in saliva substitutes on de- and remineralization of enamel in vitro. Caries Res 31:216-223.
168. Visch LL, 's-Gravenmade EJ, Schaub RMH, Van Putten WLJ, Vissink A (1986). A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 15:395-400.
169. Vissink A, 's-Gravenmade EJ, Panders AK, Vermey A, Petersen JK, Visch LL, et al. (1983). A clinical comparison between commercially available mucin- and CMC-containing saliva substitutes. Int J Oral Surg 12:232-238.
170. Vissink A, Waterman HA, 's-Gravenmade EJ, Panders AK. Vermey A (1984). Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide. J Oral Pathol 13:22-28.
171. Vissink A, 's-Gravenmade EJ, Gelhard TBFM, Panders AK, Franken MH (1985). Rehardening properties of mucin- or CMC-containing saliva substitutes on softened human enamel. Effects of sorbitol, xylitol and increasing viscosity. Caries Res 19:212-218.
172. Vissink A, de Jong HP, Busscher HJ, Arends J, 's-Gravenmade EJ (1986). Wetting properties of human saliva substitutes. J Dent Res 65:1121-1124.
173. Vissink A, Schaub RMH, van Rijn LJ, 's-Gravenmade EJ, Panders AK, Vermey A (1987). The efficacy of mucin-containing artificial saliva in alleviating symptoms of xerostomia. Gerodontology 6:95-101.
174. Vissink A, Panders AK, 's-Gravenmade EJ, Vermey A (1988a). The causes and consequences of hyposalivation. Ear Nose Throat J 67:166-176.
175. Vissink A, 's Gravenmade EJ, Panders AK, Vermey A (1988b). Treatment of hyposalivation. Ear Nose Throat J 67:179 185.
176. Vissink A, Jansma J, Spijkervet FKL, Burlage FR, Coppes RP (2003). Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14:199-212.
177. Vitolo JM, Baum BJ (2002). The use of gene transfer for the protection and repair of salivary glands. Oral Diseases 8:183-191.
178. Wagner W, Alfrink M, Haus U, Matt J (1999). Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anticancer Res 19:799-804.
179. Weerkamp AH, Wagner K, Vissink A, 's-Gravenmade EJ (1987). Effect of the application of a mucin-based saliva substitute on the oral microflora of
180. Wiesenfeld D, Stewart AM, Mason DK (1983). A critical assessment of oral lubricants in patients with xerostomia. Br Dent J 155:155-157.
181. Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD, et al. (2001). Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 50:343-352.
182. Worthington HV, Clarkson JE, Eden OB (2002). Interventions for treating oral mucositis for patients with cancer receiving treatment (Cochrane Review). In: The Cochrane Library; Issue 1. Oxford: Update Software.
183. Wright WE (1990). Pretreatment oral health care interventions for radiation patients. NCI Monogr 9:57-59.
184. Wu Q, Manning M, Schmidt-Ullrich R, Mohan R (2000). The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 46:195-205.
185. Yusof ZW, Bakri MM (1993). Severe progressive periodontal destruction due to radiation tissue injury. J Periodontol 64:1253-1258.
186. Zheng C, Baum BJ, Iadarola MJ, O'Connell BC (2000). Genomic integration and gene expression by a modified adenoviral vector. Nat Biotech 18:176-180.
187. Zimmerman RP, Mark RJ, Tran LM, Juillard GF (1997). Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys 37:571-575.
188. Zimmermann JS, Niehoff P, Wilhelm R, Schneider R, Kovàcs G, Kimmig B (1998). Prophylaxe und Therapie akuter Strahlenfolgen an Haut und Sleimhaut. Teil II: Empfehlungen der Literatur. Strahlenther Onkol 174:187-192.